AGF Management Ltd. Purchases Shares of 7,703 DexCom, Inc. (NASDAQ:DXCM)

AGF Management Ltd. acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 7,703 shares of the medical device company's stock, valued at approximately $599,000.

A number of other hedge funds have also made changes to their positions in DXCM. Covestor Ltd increased its stake in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company's stock valued at $64,000 after acquiring an additional 335 shares during the period. Harbour Investments Inc. increased its stake in shares of DexCom by 8.8% during the third quarter. Harbour Investments Inc. now owns 12,895 shares of the medical device company's stock valued at $864,000 after acquiring an additional 1,046 shares during the period. GSA Capital Partners LLP increased its stake in shares of DexCom by 129.1% during the third quarter. GSA Capital Partners LLP now owns 10,268 shares of the medical device company's stock valued at $688,000 after acquiring an additional 5,787 shares during the period. OVERSEA CHINESE BANKING Corp Ltd bought a new stake in DexCom during the third quarter worth approximately $221,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in DexCom by 6.2% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 949,565 shares of the medical device company's stock worth $63,659,000 after buying an additional 55,542 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $2.68 on Wednesday, hitting $73.38. 4,299,180 shares of the company were exchanged, compared to its average volume of 3,887,220. The company's 50 day moving average price is $83.64 and its two-hundred day moving average price is $76.95. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market capitalization of $28.67 billion, a price-to-earnings ratio of 51.31, a PEG ratio of 2.30 and a beta of 1.28.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 104,657 shares of company stock worth $8,019,422. Corporate insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DXCM. Citigroup raised their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and raised their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Morgan Stanley raised their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average target price of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.